Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

is 2.60/2.80 the correct/typical spread? ..... if so, that's a big move required just to break even.

of (much) better quality (still checking them out) are Southern Cross and Caretech

is this the announcement?

Don't think it is - but nonetheless shows what value there is in this share

All looks good to me; another ASM in the making after all the volatility has gone the sp will steadily grow over the coming months as the news comes in.

Driver I Agree ,all looks very exciting.

yet again good news comes out & as usual pump & dump. Can't understand as this company looks like a clear winner over the next few years.

fact ..... the market does not like, or perhaps does not trust this company to perform ...... if you fancy the sector, then better to look at quality like Caretech or Southern Cross

From the UPS thread.......

(Added by Master RSI on Mon 12 Feb 09:54 pm)

HML - Mid 2.325p
Reason - Chart looking ready for a BREAKOUT from a Symmetrical Triangle formed during the last month also the Indicators are at oversold and now rising, allways expecting news of their vaccine research with a GECR report on their findings

Indicators chart

Strange that @ Present you can sell 600,000 HML @ 2.29 & only buy 37,500 2.45 online anyone have any theorys as to why?

Market's short of stock, I'd say. But they don't want to put the price up to acquire it.

1.5 Mil Sells & only 200,000 Buys so far today & yet the price still holding firm. Seems to be some good support around this level now.

Does anyone know why HML has gone up by 17% this morning?

I think some news maybe expected Marcel

Keith

Henderson Morley PLC
28 February 2007
HENDERSON MORLEY PLC
(AIM:HML)

KOI CARP VACCINE UPDATE

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), the AIM
listed drug discovery company, is pleased to provide the market and its
shareholders with an update in respect of the studies relating to the Koi Carp
vaccine following the announcement made on 3 October 2006.

These studies were designed to establish if the vaccine candidate is able to
boost the immune system of vaccinated fish and included dose ranging studies to
determine at what dose the vaccine should be administered. A successful vaccine
should enable Koi exposed to virus, to mount a successful immune response
against KHV and thus prevent disease. These studies examined antibody responses
to vaccination also known as antigenicity studies.

The antigenicity studies of the Koi herpes vaccine candidate have now been
completed. The data has been analysed and the Board is pleased to announce that
100% of the vaccine recipients tested have produced a significant immune
response.

This level of immunity is a very good indicator of a successful vaccine being
developed. Further field studies are ongoing and the Company will keep
shareholders informed of progress in due course.

---ENDS---

Predicted market reaction to a 100% success rate, anybody ?

Not really a good day today issue good news.

HML seems tobe quiet a bit of buying does anyone know why?

nope .... must be nutters with too much money

New monthly GE&CR update just out.



Henderson Morley, the AIM listed drug discovery company has issued an update on studies relating to the Koi Carp vaccine following an announcement made in October last year. The studies were designed to establish if the vaccine is able to boost the immune system of vaccinated fish. It included dose ranging studies to determine the exact dosage that could be administered. If successful, Koi fish exposed to virus should be able to mount a successful immune response against KHV and prevent disease. Analysis has revealed that the 100% of the vaccine recipients tested have produced a significant immune response.

This update follows news of an agreement with AIM-listed Stem Cell Sciences, which allows SCS to explore the use of HM's L-particles and PREPS technology in the design of unique stem cell based assays.
The recently completed Cutanea Licence Agreement for new applications of ICVT, for the treatment of dermatological conditions on human, is set to boost Henderson Morleys cashflow by up to US$6.675 million over the course of the deal. This will strengthen the companys balance sheet and finance its development further, resulting in more licence deals and the undertaking of more research programmes with partners in the industry. The companys prospects remain good and we continue to believe that the share price at just over 2p does not reflect the upside potential of the companys drug research and discovery licence agreements and on-going progress it has made over the last year.
Henderson Morley offers a diverse range of novel therapeutic drug development opportunities. Its patent protected intellectual property in relation to virus infections shows evidence of having wide application, particularly with regard to vaccines for serious diseases including cancer.
We have valued the Company on a heavily risk-weighted DCF-based valuation at 4.2p per share and, with the shares trading at 2.03p, this suggests upside potential of over 80%. Any further operational progress, both in terms of drug trials and in the granting of additional licences, will reduce our risk weightings on the product development portfolio and add to that core valuation. On that basis, our stance remains buy at 2.03p.